Investor Resources
Press Releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Dec 15, 2020
LAVAL, CANADA, and CAMBRIDGE, ENGLAND – Dec 14, 2020 – Liminal BioSciences Inc. (Nasdaq: LMNL) (“Liminal BioSciences” or the “Company”), a clinical-stage biopharmaceutical company,...
-
Dec 7, 2020
LAVAL, CANADA, and CAMBRIDGE, ENGLAND – December 7, 2020 – Liminal BioSciences Inc. (Nasdaq: LMNL) (“Liminal BioSciences” or the “Company”), a clinical-stage biopharmaceutical company,...
-
Nov 13, 2020
LAVAL, CANADA, and CAMBRIDGE, ENGLAND – November 13, 2020 – Liminal BioSciences Inc. (Nasdaq: LMNL) (“Liminal BioSciences” or the “Company”), a clinical-stage biopharmaceutical...
-
Nov 12, 2020
PDUFA Target Action Date of June 5, 2021 for Ryplazim® (plasminogen) BLA Submission Ryplazim® (plasminogen) Abstracts Selected for Presentation at American Society of Hematology (ASH) in early...
-
Nov 10, 2020
LAVAL, CANADA, and CAMBRIDGE, ENGLAND – November 10, 2020 – Liminal BioSciences Inc. (Nasdaq: LMNL) (“Liminal BioSciences” or the “Company”), a clinical-stage biopharmaceutical...